US OptionsDetailed Quotes

BTAI250117C1000

Watchlist

0.05
0.000.00%

15min DelayClose Jan 7 16:00 ET

0.00High0.00Low

BioXcel Therapeutics Stock Discussion

71735916

Yesterday 00:58

Gap up?

$BioXcel Therapeutics (BTAI.US)$ 👀👀

disrudog

Yesterday 00:50

$BioXcel Therapeutics (BTAI.US)$
future of stock, medical is a new trend

Jaguar8

Dec 15, 2024 20:58

🔶December 2024 Upcoming Catalysts. Save it. In alphabetical order

$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...

Stock_Drift

Dec 11, 2024 04:16

Pre Market Ticks 5:14am 12/11

$Sportsman's Warehouse (SPWH.US)$ $Pharming Group (PHAR.US)$ $BioXcel Therapeutics (BTAI.US)$ $Gaxos.ai (GXAI.US)$ $Rigetti Computing (RGTI.US)$ $Quantum (QMCO.US)$ $MIND Technology (MIND.US)$ $Stitch Fix (SFIX.US)$ $Frequency Electronics (FEIM.US)$ $CleanCore Solutions (ZONE.US)$ $Silexion Therapeutics (SLXN.US)$ $SEALSQ Corp (LAES.US)$
📊⚡️📊

Coffee Drip

Dec 4, 2024 09:52

$BioXcel Therapeutics (BTAI.US)$ 👀

Jaguar8

Nov 22, 2024 07:29

NEWS

$BioXcel Therapeutics (BTAI.US)$
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering
NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the "Company") (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the pricing of an underwritten public offering of 5,600,000 shares of its common stock, par value $0.001 per share ("Comm...

Jaguar8

Nov 12, 2024 06:01

NEWS

$BioXcel Therapeutics (BTAI.US)$
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia
First patient randomized in SERENITY At-Home trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia
Received FDA feedback on protocol for TRANQUILITY In-Care trial of BXCL501 for agitation associated with Alzheimer's dementia (AAD)
Estimated 140 ...

Trytosaveabit

Oct 15, 2024 06:21

Update!

$BioXcel Therapeutics (BTAI.US)$ BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of Bxcl501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

Jaguar8

Sep 5, 2024 06:58

NEWS

$BioXcel Therapeutics (BTAI.US)$
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

WJJG

Jul 16, 2024 06:14

Good news! 90% increase Q over Q

$BioXcel Therapeutics (BTAI.US)$ …The Company expects unaudited revenue of approximately $1.1 million for the three months ended June 30, 2024, representing an increase of approximately 90% quarter over quarter and approximately 141% compared to the same period in 2023. Revenue growth was driven by an increase in contracting with psychiatric care clinics and behavioral health facilities using a small commercial team…

No comment yet